Recalcitrant Trichomonas vaginalis infection - A case series

International Journal of STD and AIDS

Volumn 16, Issue 7, 2005, Pages 505-509

  Waters, Laura J ^a,b   Dave, S S ^a   Deayton, J R ^a   French, P D ^a  

^a Camden Primary Care Trust   (United Kingdom)

^b CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

Algorithm; Recalcitrant; Trichomonas vaginalis

Indexed keywords

ACETARSOL; CHLORHEXIDINE; CLOTRIMAZOLE; ERYTHROMYCIN; MEBENDAZOLE; METRONIDAZOLE; NIFURATEL; NIMORAZOLE; NONOXINOL 9; PAROMOMYCIN; POVIDONE IODINE; TINIDAZOLE;

ADULT; ALGORITHM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PREVALENCE; PRIORITY JOURNAL; PROTOZOAL INFECTION; RETROSPECTIVE STUDY; REVIEW; SEXUALLY TRANSMITTED DISEASE; TRICHOMONAS VAGINALIS; TRICHOMONIASIS; UNITED KINGDOM; VAGINA FLORA; VAGINA PESSARY;

ALGORITHMS; ANIMALS; ANTITRICHOMONAL AGENTS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; TREATMENT OUTCOME; TRICHOMONAS VAGINALIS; TRICHOMONAS VAGINITIS;

EID: 22344450811     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/0956462054308314     Document Type: Review

References (66)

1. Gerbase AC, Rowley J, Heymann DHL, Berkley SFB, Pilot P. Global prevalence and incidence estimates of selected curable STDs. Sex Transm Infect 1998;74(Suppl 1):S12-16
2. Bowden FJ, Garnett GP. Why is Trichomonas vaginalis ignored? Sex Transm Infect 1999;75:372-3
3. Waghorn DJ, Tucker PK, Chia Y, et al. Collaborative approach to improve detection and management of trichomoniasis in a low prevalence district. Int J STD AIDS 1998;9:164-7
4. Cotch MF, Pastorek JG 2nd, Nugent RP, et al. Trichomonas vaginalis associated with low birth weight and preterm delivery; the vaginal infection and prematurity study group. Sex Transm Dis 1997;24:353-60
5. Cosar C, Julou L. Activite de l'(hydroxy-2, ethyl)-1-methyl-2 nitro-5 imidazole (8.823 RP) vis-à-vis des infections experimentales a Trichomonas vaginalais. Ann l'Inst Pasteur 1959;96: 238-41
6. Thurner J, Meingassner JG. Isolation of Trichomonas vaginalis resistant to metronidazole. Lancet 1978;ii:738
7. Korner B, Jensen HK. Sensitivity of Trichomonas vaginalis to metronidazole, tinidazole and nifuratel in vitro. Br J Vener Dis 1976;52:404-8
8. Josey WE. Treatment resistant Trichomoniasis. JAMA 1978;239:2035
9. Mendling W, Poli A, Magnani P. Clinical effects of nifuratel in vulvovaginal infections. A meta-analysis of metronidazole controlled trials. Arzneimittel-Forschung 2002;52:725-30
10. Gabriel G, Robertson E, Thin RN. Single dose treatment of trichomoniasis. J Int Med Res 1982;10:129-30
11. Minkowski WL, Baker CJ, Freidlander L. Single oral-dose metronidazole treatment for Trichomonas vaginalis in adolescents. J Adolesc Health Care 1981;2:41-4
12. Block B, Smyth E. The treatment of Trichomonas vaginalis vaginitis. An open controlled prospective study comparing a single dose of metronidazole tablets, benzoyl metronidazole suspension and tinidazole tablets. South Afr Med J 1985;67:455-7
13. Meri T, Jokiranta TS, Suhonen L, Meri S. Resistance of Trichomonas vaginalis to metronidazole: report of the first three cases from Finland and optimization of in vitro susceptibility testing under various oxygen concentrations. J Clin Microbiol 2000;38:763-7
14. Ralph ED, Darwish, R Austin TW, Smith EA, Pattison FL. Susceptibility of Trichomonas vaginalis strains to metronidazole: response to treatment. Sex Transm Dis 1983;10:119-22
15. Communicable Disease Surveillance Centre. Drug resistant Trichomonas vaginalis. Comm Dis Rep Wkly 1993;3:141
16. Kellock D, Mahomey CP. Sexually acquired metronidazole resistant Trichomonas vaginalis in a lesbian couple. 1996;2:60-1
17. Korner B, Jensen HK. Sensitivity of Trichomonas vaginalis to metronidazole, tinidazole and nifurantel in vitro. Br J Vener Dis 1972;52:404
18. Meingasser JG, et al. Studies on strain sensitivity of Trichomonas vaginalis to metronidazole. Br J Vener Dis 1978; 54:72
19. Gailton J, Squires S. Metronidazole resistant Trichomonas vaginalis. Lancet 1982;i:42
20. British Co-operative Clinical Group. An investigation, by questionnaire, of cases of recalcitrant vaginal trichomoniasis seen in GUM clinics in the United Kingdom. Int J STD AIDS 1992;3:24-7
21. Lossick JG. Chemotherapy of nitro-imidazole resistant vaginal trichomoniasis. Acta Univ Carol Biol 1986;30:533-45
22. Lossick JG, Kent HL. Trichomoniasis: trends in diagnosis and management. Am J Obstet Gynecol 1991;165:1217-22
23. Robertson DHH, Heyworth R, Harrison C, Lumsden WHR. Treatment failure in Trichomonas vaginalis infections in females 1. Concentrations of metronidazole in plasma and vaginal content during normal and high dosage. J Antimicrob Chemother 1986;21:373-8
24. Willmott F, Say J, Downey D, Hookham A. Zinc and recalcitrant trichomoniasis. Lancet 1983;i:1053
25. Lumsden WHR, Robertson DHH, Heyworth R, Harrison C. Treatment failure in Trichomonas vaginalis vaginitis. Genitourin Med 1988;64:217-18
26. Nitro-imidazole drugs - II. Mechanisms of resistance. J Antimicrob Chemother 1998;31:201-10
27. Rasoloson D, Tomkova E, Cammack R, Kulda J, Tachezy J. Metronidazole-resistant strains of Trichomonas vaginalis display increased susceptibility to oxygen. Parasitology 2001; 123:45-56
28. Rasoloson D, Vanacova S, Tomkova E, et al. Mechanisms of in vitro development of resistance to metronidazole in Trichomonas vaginalis. Microbiology 2002;148:2467-77
29. Quon DV, D'Oliveira CE, Johnson PJ. Reduced transcription of the ferredoxin gene in metronidazole-resistant Trichomonas vaginalis. Proc Natl Acad Sci USA 1992;89:4402-6
30. Pearlman MD, Yashar C, Ernst S, Solomon W. An incremental dosing protocol for women with severe vaginal trichomoniasis and adverse reaction to metronidazole. Am J Obstet Gynecol 1996;174:934-6
31. duBouchet L, McGregor JA, Ismail M, McCormack WM. A pilot study of metronidazole vaginal gel versus oral metronidazole for the treatment of Trichomonas vaginalis vaginitis. Sex Transm Dis 1998;25:176-9
32. Kraiden S, Lossick JG, Wilk E, Yang J, Keystone JS, Elliot K. Persistent Trichomonas vaginalis infection due to a metronidazole-resistant strain. CMAJ 1986;134:1373-4
33. Hamed KA, Studemeister AE. Successful response of metronidazole-resistant trichomonal vaginitis to tinidazole. A case report. Sex Transm Dis 1992;19:339-40
34. Grossman JH, Galask RP. Persistent vaginitis caused by metronidazole-resistant trichomonas. Obstet Gynecol 1990; 76:521-2
35. Sobel JD, Nyirjesy P, Brown W. Tinidazole therapy for metronidazole-resistant vaginal trichomoniasis. Clin Infect Dis 2001;33:1341-6
36. Durront M, Croizat B, Douillet P. Treatment of Trichomonas vaginitis with paromomycin. Gynecol Pratique 1964;15:247-51
37. Nyirjesy P, Sobel JD, Weitz MV, Leaman DJ, Gelone SP. Difficult to treat trichomoniasis: results with paromomycin cream. Clin Infect Dis 1998;26:986-3
38. Poppe WA. Nitro-imidazole resistant vaginal trichomoniasis treated with paromomycin. Eur J Obstet Gynaecol Reprod Biol 2001;96:119-20
39. Livengood III CH, Lossick JG. Resolution of resistant vaginal trichomoniasis associated with the use of intravaginal nonoxynol-9. Obstet Gynecol 1991;78:954-6
40. Sugarman B, Mummaw N. Effects of antimicrobial agents on growth and chemotaxis of Trichomonas vaginalis. Antimicrob Agents Chemother 1988;32:1323-6
41. Antonelli NM, Diehl SJ, Wright J. A randomised trial of intra-vaginal nonoxynol-9 versus oral metronidazole in the treatment of vaginal trichomoniasis. Am J Obstet Gynecol 2000;182:1008-10
42. Walker PP, Hall RE, Wilson JD. Arsenical pessaries in the treatment of metronidazole-resistant Trichomonas vaginalis. Int J STD AIDS 1997;8:473-1
43. Bowen DAL, Lewis TV. Acute arsenical poisoning due to acetarsol pessaries. BMJ 1961;i:1282-4
44. Chen MY, Smith NA, Fox EF, Bingham JS, Barlow D. Acetarsol pessaries in the treatment of metronidazole resistant Trichomonas vaginalis. Int J STD AIDS 1999;10:277-280
45. Watson PG, Pattman RS. Arsenical pessaries in the successful elimination of metronidazole-resistant Trichomomas vaginalis. M J STD AIDS 1996;7:296-7
46. Doyle JO. Acetarsol pessary dermatitis. Br J Vener Dis 1952;28:210-12
47. Mendlin W, Poli A, Magnani P. Clinical effects of nifuratel in vulvovaginal infections. A metanalysis of metronidazole controlled trials. Arzneimittel Forschung 2002;52:725-30
48. Karag'ozov I, et al. A multicenter study of the antimicrobial effect of Macmiror and Macmiror Complex in the treatment of vaginal infections. Akush Ginekol 1999;38:61-2
49. Sears SD, O'Hare J. In vitro susceptibility of Trichomonas vaginalis to 50 antimicrobial agents. Antimicrob Agents Chemother 1988;32:144-6
50. Katiyar S, Gordon V, McLaughlin G, Edlind T. Antiprotozoal activities of benzimidazoles and correlation with beta-tubulin sequence. Antimicrob Agents Chemother 1994;38: 2086-90
51. Pattman RS, Sprott MS, Kearns AM, Earnshaw M. Failure of mebendazole to cure trichomonal vaginitis resistant to metronidazole: case reports. Genitourin Med 1989;65:274-5
52. DuBouchet L, Spence MR, Rein MF, Danzig MR, McCormack WM. Multicenter comparison of clotrimazole vaginal tablets, oral metronidazole and vaginal suppositories containing sulphanilamide, aminacrine hydrochloride and allantoin in the treatment of symptomatic trichomoniasis. Sex Transm Dis 1997;24:156-60
53. Schnell JD. The incidence of vaginal candida and trichomonal infections and the treatment of Trichomonas vaginitis with clotrimazole. Postgrad Med J 1974;50:79-81S
54. Legal HP. The treatment of Trichomonas and Candida vaginitis with clotrimazole vaginal tablets. Postgrad Med J 1974;50: 81-3S
55. Lohmeyer H. Treatment of candidiasis and trichomoniasis of the female genital tract. Postgrad Med J 1974;50:78-9S
56. Debbia EA, Gampora U, Massaro S, Baldimore E, Sahito GC. In vitro activity of metronidazole alone and in combination with clotrimazole against clinical isolates of Trichomonas vaginalis. J Chemother 1996;8:96-101
57. Della Casa V, et al. Antimicrobial activity of dequalinium chloride against leading germs of vaginal infections. Arzneimittel Forschung 2002;52:699-705
58. Yu H, Tak-Yin M. The efficacy of povidone-iodine pessaries in a short, low-dose treatment regimen on candidal, trichomonal and non-specific vaginitis. Postgrad Med J 1993;69:558-61
59. Wong CA, Wilson PD, Chear TA. Povidone-iodine in the treatment of metronidazole-resistant Trichomonas vaginalis. Austr N Z J Obstet Gynaecol 1990;30:169-71
60. Alderete JF. Does lactobacillus vaccine for trichomoniasis, Solco Trichovac, induce antibody reactive # with Trichomonas vaginalis. Sex Transm Infect 1988;64:118-23
61. Sprott MS, Kearns AM, Pattman RS. Trichomonal vaginitis refractory to treatment: case report. Sex Transm Infect 1988;64:369-72
62. van der Weiden RM, van der Meijden WI, Bagchelman DH, Polderman AM. Treatment failure in trichomoniasis and persistence of the parasite after lactobacillus immunotherapy; two case reports. Eur J Obstet Gynecol Reprod Biol 1990;34:171-8
63. Martin HL, Richardson BA, Nyange PM, et al. Vaginal lactobacilli, microbial flora, and the risk of human immunodeficiency virus type 1 and sexually transmitted disease acquisition. J Infect Dis 1999;180:1863-8
64. Karkut G. Effect of lactobacillus immunotherapy on genital infections in women. Geburtshilfe Frauenheilkunde 1984;44: 311-14
65. Lushbaugh WB, Blossom AC, Shah PH, et al. Use of intravaginal microbicides to prevent acquisition of Trichomonas vaginalis infection in lactobacillus-pretreated, estrogenized young mice. Am J Trop Med Hyg 2000;63:284-9
66. Rabe LK, Hillier SL. Effect of chlorhexidine on genital microflora, Neisseria gonorrhoeae and Trichomonas vaginalis in vitro. Sex Transm Dis 2000;27:74-8